24/7 Market News Snapshot 05 June, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

June 5, 2025

DENVER, Colo., 05 June, 2025 (www.247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. has recorded significant trading activity alongside the release of encouraging results from its pivotal THIO-101 Phase 2 clinical trial, which evaluates the efficacy of the investigational agent ateganosine in combination with Regeneron’s immune checkpoint inhibitor, cemiplimab (Libtayo®), for patients with advanced non-small cell lung cancer (NSCLC) resistant to existing therapies. Today, the stock opened at $1.765 and is currently trading at $1.965, reflecting an increase of approximately 11.65% following a close of $1.760 in the previous session, signaling robust interest from investors.

The trading volume of 1.06 million shares indicates heightened market activity, potentially driven by the positive trial data. Notably, technical indicators may reinforce this bullish trend, particularly if the stock maintains levels above $1.90, which could entice further buyers. Resistance levels are established at $2.00, while support appears to hover around $1.80, presenting important thresholds for potential pricing movements.

Updated findings from the THIO-101 trial reveal a remarkable median overall survival of 17.8 months among patients receiving ateganosine, significantly surpassing the approximately 5 to 6 months typically associated with standard-of-care chemotherapy in comparable populations. This data, accompanied by a 95% confidence interval lower bound of 12.5 months, emphasizes ateganosine’s potential to advance treatment strategies for third-line NSCLC patients.

Dr. Vlad Vitoc, Chairman and CEO of MAIA, highlighted the significance of these results, noting the potential for ateganosine to extend survival in a challenging patient demographic. The company is actively pursuing regulatory pathways to expedite the approval of ateganosine, with an anticipated FDA decision potentially arriving as early as next year. MAIA remains dedicated to redefining cancer care through innovative therapeutic options, positioning ateganosine as a promising avenue in the treatment of NSCLC.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.